<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">33675422</PMID><DateCompleted><Year>2021</Year><Month>08</Month><Day>13</Day></DateCompleted><DateRevised><Year>2021</Year><Month>08</Month><Day>13</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1432-1459</ISSN><JournalIssue CitedMedium="Internet"><Volume>268</Volume><Issue>9</Issue><PubDate><Year>2021</Year><Month>Sep</Month></PubDate></JournalIssue><Title>Journal of neurology</Title><ISOAbbreviation>J Neurol</ISOAbbreviation></Journal><ArticleTitle>Effect of leuprorelin in&#xa0;bulbar function of spinal and bulbar muscular atrophy&#xa0;patients: observational study for 1&#xa0;year.</ArticleTitle><Pagination><StartPage>3344</StartPage><EndPage>3351</EndPage><MedlinePgn>3344-3351</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s00415-021-10503-y</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">This study aimed to investigate the effect of androgen suppression therapy using leuprorelin focused on the bulbar function of patients with spinal and bulbar muscular atrophy (SBMA).</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Genetically confirmed SBMA patients who consented to participate in this observational study were enrolled. Leuprorelin was subcutaneously injected every 12&#xa0;weeks. Videofluoroscopic swallowing study was performed at baseline and after androgen suppression therapy for 1 year. The primary outcome measures were the changes in the vallecular residue and pyriform sinus residue. The videofluoroscopic swallowing study data were analyzed and interpreted by two experienced physiatrists.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">A total of 40 patients with SBMA were analyzed in this study. The inter-rater reliability testing showed good agreement for the pharyngeal residue (ICC&#x2009;=&#x2009;0.84) and videofluoroscopic dysphagia scale (ICC&#x2009;=&#x2009;0.75). The vallecular residue and pyriform sinus residue after swallowing 9&#xa0;mL yogurt were significantly reduced (26.8&#x2009;&#xb1;&#x2009;22.6 to 14.6&#x2009;&#xb1;&#x2009;14.5, p&#x2009;&lt;&#x2009;0.001, 14.9&#x2009;&#xb1;&#x2009;16.9 to 7.6&#x2009;&#xb1;&#x2009;9.9, p&#x2009;&lt;&#x2009;0.001, respectively). The swallowing subscore of amyotrophic lateral sclerosis functional rating scale-revised improved after androgen suppression therapy (3.3&#x2009;&#xb1;&#x2009;0.5 to 3.5&#x2009;&#xb1;&#x2009;0.6, p&#x2009;=&#x2009;0.041).</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Leuprorelin significantly reduced the pharyngeal residue in patients with SBMA after 1 year of treatment without any serious adverse events and longitudinal studies are needed to confirm these results.</AbstractText><CopyrightInformation>&#xa9; 2021. Springer-Verlag GmbH, DE part of Springer Nature.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kang</LastName><ForeName>Min-Gu</ForeName><Initials>MG</Initials><AffiliationInfo><Affiliation>Department of Physical Medicine and Rehabilitation, Dong-A University&#x202f;College of Medicine, Busan, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gwak</LastName><ForeName>Dae-Won</ForeName><Initials>DW</Initials><AffiliationInfo><Affiliation>Department of Rehabilitation&#x202f;Medicine,&#x202f;School of Medicine, Kyungpook National University, Kyungpook National University&#x202f;Chilgok&#x202f;Hospital, Daegu, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cho</LastName><ForeName>Hee-Jin</ForeName><Initials>HJ</Initials><AffiliationInfo><Affiliation>Department of Neurology, School of Medicine, Kyungpook National University, Kyungpook National University&#x202f;Chilgok&#x202f;Hospital, Daegu, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Min</LastName><ForeName>Yu-Sun</ForeName><Initials>YS</Initials><AffiliationInfo><Affiliation>Department of Rehabilitation&#x202f;Medicine,&#x202f;School of Medicine, Kyungpook National University, Kyungpook National University&#x202f;Chilgok&#x202f;Hospital, Daegu, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Park</LastName><ForeName>Jin-Sung</ForeName><Initials>JS</Initials><Identifier Source="ORCID">0000-0001-5506-9206</Identifier><AffiliationInfo><Affiliation>Department of Neurology, School of Medicine, Kyungpook National University, Kyungpook National University&#x202f;Chilgok&#x202f;Hospital, Daegu, Republic of Korea. neurojspark@gmail.com.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D064888">Observational Study</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>03</Month><Day>06</Day></ArticleDate></Article><MedlineJournalInfo><Country>Germany</Country><MedlineTA>J Neurol</MedlineTA><NlmUniqueID>0423161</NlmUniqueID><ISSNLinking>0340-5354</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>EFY6W0M8TG</RegistryNumber><NameOfSubstance UI="D016729">Leuprolide</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D055534" MajorTopicYN="Y">Bulbo-Spinal Atrophy, X-Linked</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003679" MajorTopicYN="N">Deglutition</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003680" MajorTopicYN="Y">Deglutition Disorders</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016729" MajorTopicYN="N">Leuprolide</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009134" MajorTopicYN="Y">Muscular Atrophy, Spinal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015203" MajorTopicYN="N">Reproducibility of Results</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Androgens</Keyword><Keyword MajorTopicYN="N">Aspiration</Keyword><Keyword MajorTopicYN="N">Bulbo-Spinal Atrophy</Keyword><Keyword MajorTopicYN="N">Deglutition disorders</Keyword><Keyword MajorTopicYN="N">Leuprolide</Keyword><Keyword MajorTopicYN="N">Pneumonia</Keyword><Keyword MajorTopicYN="N">X-linked</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>12</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>2</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2021</Year><Month>2</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>3</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>8</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>3</Month><Day>6</Day><Hour>12</Hour><Minute>6</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">33675422</ArticleId><ArticleId IdType="doi">10.1007/s00415-021-10503-y</ArticleId><ArticleId IdType="pii">10.1007/s00415-021-10503-y</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Kennedy WR, Alter M, Sung JH (1968) Progressive proximal spinal and bulbar muscular atrophy of late onset. A sex-linked recessive trait. Neurology 18(7):671&#x2013;680. https://doi.org/10.1212/wnl.18.7.671</Citation><ArticleIdList><ArticleId IdType="pubmed">4233749</ArticleId></ArticleIdList></Reference><Reference><Citation>Guidetti D, Sabadini R, Ferlini A, Torrente I (2001) Epidemiological survey of X-linked bulbar and spinal muscular atrophy, or Kennedy disease, in the province of Reggio Emilia, Italy. Eur J Epidemiol 17(6):587&#x2013;591</Citation><ArticleIdList><ArticleId IdType="pubmed">11949733</ArticleId></ArticleIdList></Reference><Reference><Citation>Atsuta N, Watanabe H, Ito M, Banno H, Suzuki K, Katsuno M, Tanaka F, Tamakoshi A, Sobue G (2006) Natural history of spinal and bulbar muscular atrophy (SBMA): a study of 223 Japanese patients. Brain 129(6):1446&#x2013;1455</Citation><ArticleIdList><ArticleId IdType="pubmed">16621916</ArticleId></ArticleIdList></Reference><Reference><Citation>Bosch EP (2017) Spinal and Bulbar Muscular Atrophy (Kennedy Disease). Neurodegeneration:202</Citation></Reference><Reference><Citation>Katsuno M, Adachi H, Waza M, Banno H, Suzuki K, Tanaka F, Doyu M, Sobue G (2006) Pathogenesis, animal models and therapeutics in spinal and bulbar muscular atrophy (SBMA). Exp Neurol 200(1):8&#x2013;18</Citation><ArticleIdList><ArticleId IdType="pubmed">16513111</ArticleId></ArticleIdList></Reference><Reference><Citation>La Spada AR, Wilson EM, Lubahn DB, Harding A, Fischbeck KH (1991) Androgen receptor gene mutations in X-linked spinal and bulbar muscular atrophy. Nature 352(6330):77</Citation><ArticleIdList><ArticleId IdType="pubmed">2062380</ArticleId></ArticleIdList></Reference><Reference><Citation>La Spada AR, Roling DB, Harding AE, Warner CL, Spiegel R, Hausmanowa-Petrusewicz I, Yee W-C, Fischbeck KH (1992) Meiotic stability and genotype&#x2013;phenotype correlation of the trinucleotide repeat in X&#x2013;linked spinal and bulbar muscular atrophy. Nat Genet 2(4):301</Citation><ArticleIdList><ArticleId IdType="pubmed">1303283</ArticleId></ArticleIdList></Reference><Reference><Citation>Grunseich C, Kats IR, Bott LC, Rinaldi C, Kokkinis A, Fox D, Chen K-l, Schindler AB, Mankodi AK, Shrader JA (2014) Early onset and novel features in a spinal and bulbar muscular atrophy patient with a 68 CAG repeat. Neuromuscul Disord 24(11):978&#x2013;981</Citation><ArticleIdList><ArticleId IdType="pubmed">25047668</ArticleId><ArticleId IdType="pmc">4252652</ArticleId></ArticleIdList></Reference><Reference><Citation>Madeira JL, Souza AB, Cunha FS, Batista RL, Gomes NL, Rodrigues AS, Chadi G, Callegaro D, Mendonca B, Costa E (2017) A severe phenotype of Kennedy disease associated with a very large CAG repeat expansion. Muscle Nerve 57(1):E95&#x2013;E97</Citation><ArticleIdList><ArticleId IdType="pubmed">28877561</ArticleId></ArticleIdList></Reference><Reference><Citation>Mariotti C, Castellotti B, Pareyson D, Testa D, Eoli M, Antozzi C, Silani V, Marconi R, Tezzon F, Siciliano G (2000) Phenotypic manifestations associated with CAG-repeat expansion in the androgen receptor gene in male patients and heterozygous females: a clinical and molecular study of 30 families. Neuromuscul Disord 10(6):391&#x2013;397</Citation><ArticleIdList><ArticleId IdType="pubmed">10899444</ArticleId></ArticleIdList></Reference><Reference><Citation>Sobue G, Doyu M, Kachi T, Yasuda T, Mukai E, Kumagai T, Mitsuma T (1993) Subclinical phenotypic expressions in heterozygous females of X-linked recessive bulbospinal neuronopathy. J Neurol Sci 117(1&#x2013;2):74&#x2013;78</Citation><ArticleIdList><ArticleId IdType="pubmed">8410070</ArticleId></ArticleIdList></Reference><Reference><Citation>Schmidt BJ, Greenberg CR, Allingham-Hawkins DJ, Spriggs EL (2002) Expression of X-linked bulbospinal muscular atrophy (Kennedy disease) in two homozygous women. Neurology 59(5):770&#x2013;772</Citation><ArticleIdList><ArticleId IdType="pubmed">12221177</ArticleId></ArticleIdList></Reference><Reference><Citation>Banno H, Katsuno M, Suzuki K, Takeuchi Y, Kawashima M, Suga N, Takamori M, Ito M, Nakamura T, Matsuo K (2009) Phase 2 trial of leuprorelin in patients with spinal and bulbar muscular atrophy. Ann Neurol 65(2):140&#x2013;150</Citation><ArticleIdList><ArticleId IdType="pubmed">19259967</ArticleId></ArticleIdList></Reference><Reference><Citation>Katsuno M, Banno H, Suzuki K, Takeuchi Y, Kawashima M, Yabe I, Sasaki H, Aoki M, Morita M, Nakano I (2010) Efficacy and safety of leuprorelin in patients with spinal and bulbar muscular atrophy (JASMITT study): a multicentre, randomised, double-blind, placebo-controlled trial. Lancet Neurol 9(9):875&#x2013;884</Citation><ArticleIdList><ArticleId IdType="pubmed">20691641</ArticleId></ArticleIdList></Reference><Reference><Citation>Katsuno M, Adachi H, Doyu M, Minamiyama M, Sang C, Kobayashi Y, Inukai A, Sobue G (2003) Leuprorelin rescues polyglutamine-dependent phenotypes in a transgenic mouse model of spinal and bulbar muscular atrophy. Nat Med 9(6):768&#x2013;773</Citation><ArticleIdList><ArticleId IdType="pubmed">12754502</ArticleId></ArticleIdList></Reference><Reference><Citation>Plosker GL, Brogden RN (1994) Leuprorelin. Drugs 48(6):930&#x2013;967</Citation><ArticleIdList><ArticleId IdType="pubmed">7533699</ArticleId></ArticleIdList></Reference><Reference><Citation>Wechsel H, Zerbib M, Pagano F, Coptcoat M (1996) Randomized open labelled comparative study of the efficacy, safety and tolerability of leuprorelin acetate 1M and 3M depot in patients with advanced prostatic cancer. Eur Urol 30:7&#x2013;14</Citation><ArticleIdList><ArticleId IdType="pubmed">8977984</ArticleId></ArticleIdList></Reference><Reference><Citation>Nam HS, Beom J, Oh B-M, Han TR (2013) Kinematic effects of hyolaryngeal electrical stimulation therapy on hyoid excursion and laryngeal elevation. Dysphagia 28(4):548&#x2013;556</Citation><ArticleIdList><ArticleId IdType="pubmed">23605128</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosenbek JC, Robbins JA, Roecker EB, Coyle JL, Wood JL (1996) A penetration-aspiration scale. Dysphagia 11(2):93&#x2013;98</Citation><ArticleIdList><ArticleId IdType="pubmed">8721066</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim J, Oh B-M, Kim JY, Lee GJ, Lee SA, Han TR (2014) Validation of the videofluoroscopic dysphagia scale in various etiologies. Dysphagia 29(4):438&#x2013;443</Citation><ArticleIdList><ArticleId IdType="pubmed">24658847</ArticleId></ArticleIdList></Reference><Reference><Citation>Han TR, Paik N-J, Park J-W, Kwon BS (2008) The prediction of persistent dysphagia beyond six months after stroke. Dysphagia 23(1):59&#x2013;64</Citation><ArticleIdList><ArticleId IdType="pubmed">17602263</ArticleId></ArticleIdList></Reference><Reference><Citation>Takeuchi Y, Katsuno M, Banno H, Suzuki K, Kawashima M, Atsuta N, Ito M, Watanabe H, Tanaka F, Sobue G (2008) Walking capacity evaluated by the 6-minute walk test in spinal and bulbar muscular atrophy. Muscle Nerve 38(2):964&#x2013;971</Citation><ArticleIdList><ArticleId IdType="pubmed">18642379</ArticleId></ArticleIdList></Reference><Reference><Citation>Brooks D, Solway S, Gibbons W (2003) ATS statement on six-minute walk test. Am J Respir Crit Care Med 167(9):1287</Citation><ArticleIdList><ArticleId IdType="pubmed">12714344</ArticleId></ArticleIdList></Reference><Reference><Citation>Cedarbaum JM, Stambler N, Malta E, Fuller C, Hilt D, Thurmond B, Nakanishi A, Group BAS, Group AclotBS (1999) The ALSFRS-R: a revised ALS functional rating scale that incorporates assessments of respiratory function. J Neurol Sci 169(1&#x2013;2):13&#x2013;21</Citation><ArticleIdList><ArticleId IdType="pubmed">10540002</ArticleId><ArticleId IdType="pmc">10540002</ArticleId></ArticleIdList></Reference><Reference><Citation>Chahin N, Klein C, Mandrekar J, Sorenson E (2008) Natural history of spinal-bulbar muscular atrophy. Neurology 70(21):1967&#x2013;1971</Citation><ArticleIdList><ArticleId IdType="pubmed">18490617</ArticleId></ArticleIdList></Reference><Reference><Citation>Copay AG, Subach BR, Glassman SD, Polly DW Jr, Schuler TC (2007) Understanding the minimum clinically important difference: a review of concepts and methods. Spine J 7(5):541&#x2013;546</Citation></Reference><Reference><Citation>Oeffinger D, Bagley A, Rogers S, Gorton G, Kryscio R, Abel M, Damiano D, Barnes D, Tylkowski C (2008) Outcome tools used for ambulatory children with cerebral palsy: responsiveness and minimum clinically important differences. Dev Med Child Neurol 50(12):918&#x2013;925</Citation><ArticleIdList><ArticleId IdType="pubmed">19046185</ArticleId><ArticleId IdType="pmc">2990955</ArticleId></ArticleIdList></Reference><Reference><Citation>Wright A, Hannon J, Hegedus EJ, Kavchak AE (2012) Clinimetrics corner: a closer look at the minimal clinically important difference (MCID). J Manual Manip Ther 20(3):160&#x2013;166</Citation></Reference><Reference><Citation>Grunseich C, Fischbeck KH (2015) Spinal and bulbar muscular atrophy. Neurol Clin 33(4):847&#x2013;854</Citation><ArticleIdList><ArticleId IdType="pubmed">26515625</ArticleId><ArticleId IdType="pmc">4628725</ArticleId></ArticleIdList></Reference><Reference><Citation>Banno H, Katsuno M, Suzuki K, Tanaka S, Suga N, Hashizume A, Mano T, Araki A, Watanabe H, Fujimoto Y (2017) Swallowing markers in spinal and bulbar muscular atrophy. Ann Clin Transl Neurol 4(8):534&#x2013;543</Citation><ArticleIdList><ArticleId IdType="pubmed">28812043</ArticleId><ArticleId IdType="pmc">5553229</ArticleId></ArticleIdList></Reference><Reference><Citation>Finsterer J (2010) Perspectives of Kennedy&#x2019;s disease. J Neurol Sci 298(1):1&#x2013;10</Citation><ArticleIdList><ArticleId IdType="pubmed">20846673</ArticleId></ArticleIdList></Reference><Reference><Citation>Shore N, Abrahamsson P-A, Anderson J, Crawford E, Lange P (2013) New considerations for ADT in advanced prostate cancer and the emerging role of GnRH antagonists. Prostate Cancer Prostatic Dis 16(1):7</Citation><ArticleIdList><ArticleId IdType="pubmed">22751146</ArticleId></ArticleIdList></Reference><Reference><Citation>Schmid P, Untch M, Koss&#xe9; V, Bondar G, Vassiljev L, Tarutinov V, Lehmann U, Maubach L, Meurer J, Wallwiener D (2007) Leuprorelin acetate every-3-months depot versus cyclophosphamide, methotrexate, and fluorouracil as adjuvant treatment in premenopausal patients with node-positive breast cancer: the TABLE study. J Clin Oncol 25(18):2509&#x2013;2515</Citation><ArticleIdList><ArticleId IdType="pubmed">17577027</ArticleId></ArticleIdList></Reference><Reference><Citation>Chrisp P, Sorkin EM (1991) Leuprorelin. Drugs Aging 1(6):487&#x2013;509</Citation><ArticleIdList><ArticleId IdType="pubmed">1794035</ArticleId></ArticleIdList></Reference><Reference><Citation>Suzuki K, Kastuno M, Banno H, Sobue G (2009) Pathogenesis-targeting therapeutics for spinal and bulbar muscular atrophy (SBMA). Neuropathology 29(4):509&#x2013;516</Citation><ArticleIdList><ArticleId IdType="pubmed">19486304</ArticleId></ArticleIdList></Reference><Reference><Citation>Jones B (2012) Normal and abnormal swallowing: imaging in diagnosis and therapy. Springer, Berlin</Citation></Reference><Reference><Citation>Mulheren RW, Inamoto Y, Odonkor CA, Ito Y, Shibata S, Kagaya H, Fernandez MG, Saitoh E, Palmer JB (2019) The Association of 3-D volume and 2-D area of post-swallow pharyngeal residue on CT imaging. Dysphagia 34(5):665&#x2013;672</Citation><ArticleIdList><ArticleId IdType="pubmed">30637511</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>